Combioxin SA
Combioxin SA is a Swiss clinical-stage biotechnology company developing first-in-class life-saving drugs for severe infections.
About
Combioxin SA is a Swiss-based clinical-stage biotechnology company founded in 2015 and focused on the development of disruptive, first-in-class treatments for severe and resistant infections. Their lead product, CAL02, is a novel liposomal anti-toxin agent designed to neutralize virulence effectors from pathogens that cause organ failure and lethal complications in severe infections, particularly community-acquired bacterial pneumonia. CAL02 works as a broad-spectrum, non-antibiotic drug that can be used alongside standard antibiotic treatments, actively addressing both drug-sensitive and drug-resistant infections. The company engages in international partnerships for commercialization and is committed to transforming the standard of care in critical care infections globally.
Products & Services
- CAL02 – a first-in-class liposomal anti-toxin agent for severe community-acquired bacterial pneumonia and severe infections
Use Cases & Case Studies
- CAL02 as adjunctive therapy to antibiotics for patients with severe community-acquired bacterial pneumonia in intensive care
- CAL02 use to prevent organ failure and reduce ICU stay in patients with severe pneumonia
Partnerships & Collaborations
- Worldwide licensing agreement with Eagle Pharmaceuticals for the commercial rights to CAL02
Awards & Recognition
- FDA Fast-Track Designation for CAL02
- Qualified Infectious Disease Product (QIDP) designation by FDA
- Clinical trial results ranked as 'a medical breakthrough' in The Lancet Infectious Diseases